RSS   Newsletter   Contact   Advertise with us

Casebia Therapeutics appoints Stephen Kennedy as SVP

Christian Fernsby | Cambridge, Mass., USA | June 5, 2019
Casebia TherapeuticsCasebia Therapeutics, an editing company discovering and developing curative treatments for genetic diseases, appointed Stephen Kennedy as senior vice president, head of technical operations.
Before joining Casebia, Mr. Kennedy served as the Chief Operating Officer for Histogenics Corporation, a restorative cell therapy company.

Prior to his time at Histogenics, Mr. Kennedy spent three years as the Executive Vice President of Research and Development at Mascoma Corp., and one year as the Executive Director at The Novartis/MIT Center for Continuous Manufacturing.

Mr. Kennedy spent over a decade at Genzyme where he worked his way up to Senior Vice President of Biologics Operations, where he oversaw the development of therapeutic protein capacity for the company.

Mr. Kennedy's experience spans the globe as he’s held positions in Finland, France and Belgium.

He holds a Bachelor of Science in Chemical Engineering from The University of Michigan.

Mr. Kennedy then earned his M.S. in Chemical Engineering from the University of Rochester, and his Master of Business Administration from Boston University.

 LATEST MOVES FROM Massachusetts